Clinical data were obtained from the LEAD-1 study [66], which compared the effects of glimepiride with two doses of the GLP-1 analog liraglutide (1.2 mg and 1.8 mg) or rosiglitazone (4 mg) in patients with T2DM. This evidence concerns the gene GCG and type 2 diabetes mellitus.